Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds-News

13G Filing: Knoll Capital Management Raises Stake in Synthetic Biologics, Inc. (SYN)

Published on March 1, 2016 at 3:00 pm by Meena Krishnamsetty in Hedge Funds, News
Page 1 of 7
Next >>

Fred Knoll‘s Knoll Capital Management has issued three Form 13G filings today, with one of them being on Synthetic Biologics Inc (NYSEMKT:SYN), which ranked as the investment firm’s third-largest holding at the end of 2015. That holding has since been increased by another 1.02 million shares according to the current filing, lifting it to 4.75 million shares and pushing the fund’s percentage of ownership of the stock to 5.2%. The full content of the filing can be found below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Knoll Capital Management 0 4,754,557 0 4,754,557 4,754,557 5.2%
Fred Knoll 0 4,754,557 0 4,754,557 4,754,557 5.2%
Gakasa Holdings 0 4,754,557 0 4,754,557 4,754,557 5.2%

Follow Fred Knoll's Knoll Capital Management

Page 1 of 7 SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G*
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2
(Amendment No. ___)*
Synthetic Biologics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)

87164U102
(CUSIP Number)

February
16, 2016
(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes)

Page 1 of 7

Follow Theriva Biologics Inc. (NYSEMKT:TOVX)








Page 1 of 7
Next >>

Show more...Show less